RecruitingPhase 2NCT06989359
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ADARx Pharmaceuticals, Inc.
- Principal Investigator
- Aditya Patel, MD, M.DADARx Pharmaceuticals, Inc.
- Intervention
- ADX-038 Dose Level 2(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (12)
- ADARx Clinical Site, Shreveport, Louisiana, United States
- ADARx Clinical Site, Shelby, Michigan, United States
- ADARx Clinical Site, Dakota Dunes, South Dakota, United States
- ADARx Clinical Site, Dallas, Texas, United States
- ADARx Clinical Site, Houston, Texas, United States
- ADARx Clinical Site, Wollongong, New South Wales, Australia
- ADARx Clinical Site, Pok Fu Lam, Hong Kong
- ADARx Clinical Site, Shatin, Hong Kong
- ADARx Clinical Site, Gyeonggi-do, New South Wales, South Korea
- ADARx Clinical Site, Seoul, New South Wales, South Korea
- ADARx Clinical Site, Cheonan, South Korea
- ADARx Clinical Site, Seoul, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06989359 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital
- RECRUITINGPHASE3NCT06963827A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney ConditionTakeda